1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Diaceutics PLC

Diaceutics PLC

DIUXF
Diaceutics PLCUS flagOther OTC
2.00
USD
- -
- -
169.26MMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
0.07
0.11
0.23
0.21
0.16
0.17
0.23
0.28
0.38
0.45
Basic EPS, GAAP
0.01
0.01
0.01
0.01
- -
0.01
0.01
-0.02
-0.02
- -
Free Cash Flow per Basic Share
0.01
0.02
-0.05
-0.06
-0.08
-0.06
- -
-0.04
-0.05
-0.06
Dividend per Share
- -
- -
0.01
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.01
0.02
0.05
0.04
0.04
0.05
0.07
0.05
0.48
0.49
Tangible Book Value per Share
0.01
0.02
0.03
0.26
0.4
0.33
0.32
0.3
0.29
0.29
Basic Weighted Avg Shares
70
70
45
64
78
84
84
84
84
85
Sales/Revenue/Turnover
5
7
10
13
13
14
20
24
32
38
Operating Margin (%)
19.23
12.23
13.55
15.53
-2.13
3.94
2.95
-12.73
-7.63
0.11
Depreciation Expense
- -
- -
- -
- -
1
2
3
5
5
6
Net Income, GAAP
1
1
1
- -
- -
1
1
-2
-2
- -
Effective Tax Rate (%)
4.82
15.5
27.92
19.92
- -
- -
- -
- -
- -
67.88
Profit Margin (%)
16.28
9
6.1
2.96
2.07
4.02
3.71
-7.37
-5.3
0.25
Working Capital
2
3
3
16
31
27
27
24
22
21
LT Debt
1
2
1
- -
- -
1
1
1
1
1
Total Equity
1
2
3
20
40
41
43
41
40
40
Return on Invested Capital (%)
- -
23.26
19.33
12.45
- -
- -
- -
- -
- -
0.03
Return on Capital (%)
- -
26.37
17.74
12.99
- -
- -
- -
- -
- -
0.27
Return on Common Equity (%)
- -
60.02
33.76
15.86
8.57
14.74
14.83
-35.91
-7.57
0.23

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
0.17%
1.56%
Free Cash Flow
- -
-348.93%
32.35%
Net Income, GAAP
- -
-61.39%
-105.7%
Sales/Revenue/Turnover
- -
25.29%
19.53%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
24
2024
- -
- -
- -
- -
32
2025
- -
- -
- -
- -
38

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.02
2024
- -
- -
- -
- -
-0.02
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Ryan Keeling
Full Time Employees
184
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Address
Building Two Belfast United Kingdom BT9 6GW
IPO Date
May 29, 2020
Website
diaceutics.com
Similar Companies
Acer Medical Inc. (6857.TWO)
Genetic Technologies Limited (GNTLF)
IDL Diagnostics AB (publ) (IDLDX.ST)
Izotropic Corporation (IZO.CN)
Global Cord Blood Corporation (CORBF)
Biosynex S.A. (ALBIO.PA)
Business
Diaceutics PLC (DIUXF) provides diagnostic commercialization solutions, data analytics, and implementation services to pharmaceutical and biotech companies worldwide for the development and launch of precision medicine diagnostics. The company operates the DXRX platform, which integrates real-world diagnostic testing data from a global network of over 52,000 laboratories across 53 countries; offers insight solutions including Signal for actionable physician alerts, Testing Rate Tracker for biomarker testing rates, Lab Segmentation for lab insights, and Physician Segmentation for US physician testing behaviors; delivers engagement solutions such as Lab Engage with DXRX Lab Talks and Alerts, and Physician Engage for targeted notifications; provides advisory services encompassing Strategy and Planning with tactical playbooks, Insights for commercialization barriers, Market Access analysis, Education and Content programs, Impact Assessments, and ad-hoc Consulting; and supplies scientific services like Ring Studies, Lab Report Optimization, Pharma Lab Induction, Lab Training, and EQA Support. Diaceutics serves pharma, biotech, and diagnostic firms targeting precision medicine in oncology and rare diseases, with operations centered in Belfast, Northern Ireland, and additional offices in the US, Ireland, and Singapore. Founded in 2005 and headquartered at First Floor, Building Two, Dataworks at Kings Hall Health and Wellbeing Park, Belfast, County Antrim, BT9 6GW, Northern Ireland, the company maintains two main segments: Insight & Engagement Solutions via DXRX data products and Scientific & Advisory Services. In recent developments, Diaceutics signed an enterprise-wide PMx commercialization partnership with Partner Therapeutics in March 2025 valued at up to £13.0 million through 2028, supporting the US launch of Bizengri following FDA approval in December 2024; expanded this PMx agreement in July 2025 amid early successes; grew customer therapeutic brands by 17% and secured a total of eight enterprise agreements generating £10.1 million in annual recurring revenue as of H1 2025; and projects identification of 800,000 eligible patients via DXRX by year-end 2025.